// App-Quantinova.ai

e18042 : Predicting unreported clinical trial efficacy using an ex-vivo tumor platform: Pembrolizumab+pt+5-FU vs. extreme in recurrent head and neck squamous cell carcinoma.

Researchers

Presenter

  • Munisha Smalley

Principal Investigators

  • Saravanan Thiyagarajan

  • Biswanath Majumder

  • Nandini Pal Basak

  • Abhishek Basu

  • Padhma Radhakrishnan

  • Pradeep Kumar Kar

  • Manjusha Biswas

  • Basava U Shanthappa

  • Hans Gertje

  • Mark Lawson

  • K S Sabitha

  • K Jay G Ray

  • Govind Babu Kanakasetty

  • Pradip K Majumder

  • Aaron Goldman

Medical Centers

  • Mitra Biotech Pvt Ltd., Woburn, MA

  • Mitra Biotech Pvt Ltd., Bangalore, India

  • Mitra Biotech RxDx, Woburn, MA

  • Kidwai Memorial Institute of Oncology, Departments of Oral Surgery and Medical Oncology, Bangalore, India

  • Department of Oral Pathology, Burdwan Dental College and Hospital, West Bengal, India

  • Kidwai Memorial Institute of Oncology, Bangalore, India

Locations

  • United States

  • India

Companies

  • Mitra Biotech Pvt Lt

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Erbitux

  • Adrucil injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00122460

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved